

1 **Association of D-dimer and fibrinogen magnitude with hypercoagulability by thromboelastography**
2 **in severe COVID-19**

3 Abhimanyu Chandel^{1¶*}, Saloni Patolia^{2¶}, Mary Looby^{3¶}, Heidi J. Dalton^{4&} Najeebah Bade^{5&},
4 Vikramjit Khangoora^{6&}, Mehul Desai^{7&}, James Lantry^{7&}, Erik Osborn^{7&}, Svetolik Djurkovic^{7&},
5 Daniel Tang^{8&}, Steven D. Nathan^{6&}, Christopher S. King^{6¶}

6

7 ¹Department of Pulmonology and Critical Care, Walter Reed National Military Medical Center,
8 Bethesda, MD, USA

9 ²Virginia Commonwealth University School of Medicine, Richmond, VA, USA

10 ³Department of Pharmacy, Inova Fairfax Hospital, Falls Church, VA, USA

11 ⁴Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, USA

12 ⁵Department of Hematology, Inova Fairfax Hospital, Falls Church, VA, USA

13 ⁶Department of Advanced Lung Disease and Transplant, Inova Fairfax Hospital, Falls Church,
14 VA, USA

15 ⁷Department of Medical Critical Care, Inova Fairfax Hospital, Falls Church, VA, USA

16 ⁸Department of Cardiothoracic Surgery, Inova Fairfax Hospital, Falls Church, VA, USA

17

18 * Corresponding Author

19 E-mail: Abhimanyu.chandel.mil@mail.mil (AC)

20

21 ¶These authors contributed equally to this work.

22 &These authors also contributed equally to this work.

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39 **Abstract**

40 **Introduction:** D-dimer concentration has been used to identify candidates for intensified
41 anticoagulant treatment for both venous thromboembolism prevention and mitigation of the
42 microthrombotic complications associated with COVID-19. Thromboelastography (TEG)
43 maximum amplitude (MA) has been validated as an indicator of hypercoagulability and MA \geq 68
44 mm has been utilized as a marker of hypercoagulability in other conditions. We evaluated the
45 relationship between coagulation, inflammatory, and TEG parameters in patients with COVID-
46 19 on extracorporeal membrane oxygenation (ECMO).

47 **Methods:** We performed a single center retrospective analysis of consecutive patients that
48 received ECMO for the treatment of COVID-19. TEG, inflammatory, and coagulation markers
49 were compared in patients with and without thrombotic complications. Correlation tests were
50 performed to identify the coagulation and inflammatory markers that best predict
51 hypercoagulability as defined by an elevated TEG MA.

52 **Results:** 168 TEGs were available in 24 patients. C-reactive protein and fibrinogen were
53 significantly higher in patients that developed a thrombotic event versus those that did not
54 ($p=0.038$ and $p=0.043$ respectively). D-dimer was negatively correlated with TEG MA ($p<0.001$)
55 while fibrinogen was positively correlated ($p<0.001$). A fibrinogen > 441 mg/dL had a sensitivity
56 of 91.2% and specificity of 85.7% for the detection of MA \geq 68 mm.

57 **Conclusions:** In critically ill patients with COVID-19, D-dimer concentration had an inverse
58 relationship with hypercoagulability as measured by TEG MA. D-dimer elevation may reflect
59 severity of COVID-19 related sepsis rather than designate patients likely to benefit from

60 anticoagulation. Fibrinogen concentration may represent a more useful marker of
61 hypercoagulability in this population.

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79 **Introduction**

80 Critically ill coronavirus disease 2019 (COVID-19) patients have been noted to display features
81 of hypercoagulopathy involving both microthrombosis and macrothrombotic events. These
82 patients have frequently been observed to have significant laboratory abnormalities that are
83 compatible with a hypercoagulable state including severe derangements of D-dimer, fibrinogen,
84 and thromboelastography (TEG) parameters.[1, 2]

85 Thrombosis, including venous thromboembolism (VTE), arterial thrombosis, and
86 microthrombosis, is thought to be a sequelae of the pathogenesis of severe COVID-19 infection.
87 Autopsies of COVID-19 infected patients have demonstrated the presence of pulmonary
88 microthrombi and it has been postulated that microthrombus formation may contribute to end-
89 organ dysfunction and failure.[3-5]

90 One approach to the management of critically ill COVID-19 patients has been the use of
91 therapeutic anticoagulation to mitigate this hypercoagulability. Multiple local and regional
92 organizations have advocated for the use of D-dimer testing and threshold values as a means to
93 guide the intensity of anticoagulant therapy.[6, 7] This practice is based in part on observational
94 evidence suggesting that treatment of patients with COVID-19 with anticoagulation is associated
95 with improved in-hospital survival.[8] Additionally, the magnitude of D-dimer elevation
96 independently correlates to risk of VTE in general medical patients, and furthermore, correlates
97 to mortality in COVID-19.[9, 10]

98 However, D-dimer is a non-specific marker that is produced as the result of fibrin formation and
99 degradation as a downstream product of thrombin cleavage of fibrinogen.[11] Although elevated
100 D-dimer levels are observed with the presence of VTE, D-dimer is non-specific and often

101 markedly elevated in other conditions including sepsis in the absence of clinically evident
102 VTE.[12] It is not clear that the magnitude of D-dimer elevation in COVID-19 correlates with
103 hypercoagulability or clinical conditions that are likely to benefit from anticoagulation.[2] It is
104 also not clear that D-dimer represents a superior marker for hypercoagulability over other
105 available tests of the coagulation system or inflammatory markers including fibrinogen, ferritin,
106 and C-reactive protein (CRP). TEG maximum amplitude (MA), a measure of clot strength
107 accounting for platelet and fibrin contributions, has been validated as a marker of
108 hypercoagulability in a wide range of conditions and has been found to correlate with
109 macrothrombotic events.[13] Previous studies have defined hypercoagulability by a TEG MA \geq
110 68 mm.[14] In this study we evaluated the relationship between commonly utilized laboratory
111 parameters and hypercoagulability as represented by TEG MA.

112 **Methods**

113 We performed a retrospective medical record review of consecutive hospitalized patients
114 admitted to Inova Fairfax Hospital, a tertiary care referral center in Falls Church, Virginia, USA
115 between March 5, 2020 and May 29, 2020 with a diagnosis of COVID-19 confirmed by positive
116 PCR testing and undergoing extracorporeal membrane oxygenation (ECMO). The study was
117 approved by the Institutional Review Board (IRB# 18-3317) at Inova Fairfax Hospital.
118 Only patients on ECMO were evaluated as it is standard practice at our institution to obtain daily
119 TEGs as part of the routine care of these patients. TEG was performed using the TEG 5000
120 platform (Haemonetics Corporation, Braintree, MA). TEGs were conducted using citrated whole
121 blood, kaolin activator, and heparinase for patients on heparin. D-dimer values are reported by
122 our laboratory in ug/mL of fibrinogen equivalent units (FEU).

123 Data was abstracted in a structured format by one of the authors (SP) and entered into a
124 customized data form. Data was collected when available for standard TEG parameters (R-time
125 and MA), D-dimer, fibrinogen, CRP, and ferritin. D-dimer values > 20 ug/mL FEU were
126 recorded as 20 ug/mL FEU and R-time reported as > 60 min was denoted as 60 min. TEG and
127 inflammatory markers or coagulation studies were compared if drawn within 24 hours. For
128 patients on systemic heparin, TEG parameters with the use of heparin neutralization were
129 collected. Demographic data, anticoagulant usage, and clinical outcomes including bleeding,
130 macrothrombotic complications, and time on ECMO were recorded. Diagnosis of a
131 macrothrombotic event (deep vein thrombosis, pulmonary embolism, or other large vessel
132 venous or arterial blood clot) was recorded based on radiographic report finalized during
133 hospitalization or point-of-care ultrasound findings consistent with VTE in patients with acute
134 decompensation and suspected pulmonary embolism. Bleeding was defined as a clinically
135 observed event, as reported by the treating clinician, that necessitated transfusion of red blood
136 cells.

137 **Statistical Analysis**

138 Distribution of all continuous data was examined for normality using visual inspection and the
139 Wilk Shapiro test. Laboratory characteristics of the groups are presented as the median and
140 interquartile range and compared using the Wilcoxon rank sum test. Categorical data are
141 presented as counts with proportions and compared using Fisher's exact test (two-tailed). A p
142 value < 0.05 was considered statistically significant.

143 MA, fibrinogen, and CRP had skewed distributions. To reduce the impact of outliers and for
144 parametric modeling, the natural log of these variables is used in graphical presentations and

145 analyses. Associations of continuous data are presented graphically using linear regression
146 models and plotted using natural log (ln) scales. MA values were categorized into values ≥ 68
147 mm and < 68 mm and the diagnostic accuracy of fibrinogen and CRP in predicting MA is
148 presented using a receiver operator characteristic curve, summarized using the area under the
149 curve (AUC) together with 95% CIs, and compared utilizing the empirical method. All statistical
150 analyses were performed using STATA version 14 (StataCorp LP; College Station, TX, USA).

151 **Results**

152 Twenty-four consecutive patients with COVID-19 requiring ECMO support were included in the
153 final cohort. Patients were grouped by the presence or absence of diagnosed macrothrombosis
154 during hospitalization. Twelve patients developed macrothrombosis either while receiving
155 ECMO or after this therapy was discontinued (9 deep vein thromboses, 2 pulmonary emboli, and
156 one episode of embolic mesenteric ischemia). Two patients developed bleeding complications
157 (hemoptysis and gastrointestinal hemorrhage). Demographic data, laboratory values, and clinical
158 outcomes between groups are displayed in Table 1. Patients with imaging confirmed
159 macrothrombosis were significantly more likely to have higher median CRP and fibrinogen
160 values.

161

162

163

164

165

166 **Table 1. Characteristics of patients categorized by diagnosed macrothrombosis.**

	All Subjects	Macrothrombosis	No thrombosis	P Value
	n=24	n=12	n=12	
Age (years)	46 (37, 52)	50 (43, 52)	45 (31, 53)	0.370
Gender, women	16.7	0	25	0.093
Race, non-white	83.3	91.7	75.0	0.590
Time prior to ECMO initiation (days)	5 (2, 7)	6 (3, 8)	5 (2, 6)	0.400
MA (mm)	72.8 (71.2, 78.4)	74.9 (72.3, 79.9)	72.1 (70.6, 77.9)	0.225
R time (min)	10.4 (8.5, 12.8)	11.6 (8.6, 12.5)	10.3 (8.4, 13.1)	0.864
D-dimer (ug/mL)	3.5 (2.4, 7.9)	3.1 (2.4, 4.6)	3.9 (2.5, 9.0)	0.312
Fibrinogen (mg/dL)	543.5 (476.5, 674.6)	582.5 (538.4, 758.4)	501.5 (447.5, 575.9)	0.043
CRP (mg/dL)	11.1 (4.8, 17.8)	15.3 (8.4, 26.9)	7.55 (3.2, 12.3)	0.038
Ferritin (ng/mL)	985.2 (631.0, 2047.9)	1004.6 (577.8, 2258.3)	965.8 (730.7, 1785.0)	0.922
Bleeding complication	8.3	16.7	0	0.478
Time on ECMO (days)	13 (9, 20)	16 (12, 20)	10 (8, 16)	0.111
Death during hospitalization	20.8	33.3	8.3	0.317

167 Data presented as median (25th percentile, 75th percentile) or n (%) unless otherwise indicated
 168 ECMO, extracorporeal membrane oxygenation; MA, maximum amplitude; CRP, C-reactive
 169 protein
 170

171 All patients studied received therapeutic anticoagulation per institutional ECMO protocol with
 172 occasional cross-over between specific anticoagulant. Forty-six TEGs were obtained on heparin
 173 while 122 TEGs were obtained on bivalirudin. Matching D-dimer values were available for all
 174 TEGs and there were 7 instances where matching fibrinogen values were not obtained.

175 D-dimer was examined as a possible predictor of MA in patients on heparin, on bivalirudin, and
 176 in aggregate. D-dimer was found to be significantly negatively correlated with MA in all three
 177 analyses (p=0.001, <0.001, and <0.001 respectively) (Fig 1A). D-dimer explained little of the
 178 variance in MA values (adjusted R²=0.221, 0.112, and 0.162 respectively). Fibrinogen was found

179 to be positively correlated with MA. Ln(fibrinogen) explained over 50% of the variance in
180 ln(MA) (adjusted $R^2 = 0.567$) and the association was significant for patients on heparin,
181 bivalirudin, and in aggregate ($p < 0.001$) (Fig 1B). With ln(fibrinogen) in the model, CRP and
182 ferritin were examined as additional predictors and were not significant.

183 **Fig 1. Linear regression model.** (A) Ln(MA) vs. ln(D-dimer) with linear regression for patients
184 on heparin, bivalirudin, and aggregated patients. (B) Ln(MA) vs. ln(fibrinogen) with linear
185 regression for patients on heparin, bivalirudin, and aggregated patients.

186 All TEG MA values were then categorized as ≥ 68 mm and < 68 mm. MA values ≥ 68 mm were
187 associated with lower absolute D-dimer values and higher absolute fibrinogen values ($p < 0.001$).
188 Receiver operator curves (ROC) based on CRP (Fig 2) and fibrinogen levels (Fig 3) were
189 estimated. CRP accuracy in classifying MA ≥ 68 mm was poor (AUC 0.707 CI: 0.606-0.807)
190 while classification accuracy of fibrinogen for a MA ≥ 68 mm was excellent (AUC 0.934 CI:
191 0.883-0.984). AUC was greater for the ROC curve utilizing fibrinogen as a predictor ($p < 0.001$).
192 A fibrinogen cutoff of 441 mg/dL to predict MA ≥ 68 mm (sensitivity of 91.2%, specificity
193 85.7%) satisfies the closest-to-(0, 1) criterion for threshold selection.

194 **Fig 2. ROC curve for C-reactive protein as a predictor of MA ≥ 68 mm.**

195 **Fig 3. ROC curve for fibrinogen as a predictor of MA ≥ 68 mm.**

196 **Discussion**

197 The emergence of COVID-19 as a global pandemic has necessitated the implementation of
198 treatment protocols based on expert opinion given limited available clinical data. D-dimer has
199 been cited as correlating with worse clinical outcomes in COVID-19 and coagulopathy has been

200 noted to be a common feature of severe infection.[3-5, 10] However, absolute magnitude of D-
201 dimer has not been convincingly demonstrated to be linked to an increased risk of small or large
202 vessel thrombosis in this disease.[2]

203 In this present study we aimed to evaluate the correlation of commonly available measures of
204 coagulopathy (D-dimer and fibrinogen) with a validated reference standard (TEG). TEG MA
205 values have previously been demonstrated to correlate with degree of hypercoagulability in a
206 wide number of clinical conditions.[13]

207 Our results demonstrate that in this population of critically ill COVID-19 patients receiving
208 ECMO therapy, absolute D-dimer magnitude did not correlate positively with degree of
209 hypercoagulability as measured by TEG MA. On the contrary; D-dimer concentration was
210 actually inversely related to MA in our study population. This finding was unexpected and the
211 physiologic basis is uncertain.

212 A number of national guidelines have been published regarding the management of COVID-19
213 coagulopathy. These guidelines, in our view, are appropriately conservative with respect to
214 recommendations related to the use of therapeutic dosing of anticoagulants for the management
215 of critically ill patients with COVID-19.[2, 3, 15] Despite these guidelines, local and regional
216 hospital practices vary widely, with some recommending D-dimer thresholds to aid the decision
217 regarding initiation and intensity of anticoagulation. Based on our data, we speculate that
218 commonly noted severe D-dimer aberrations are likely markers of COVID-19 related sepsis
219 rather than degree of hypercoagulability. In the absence of additional data, it seems prudent to
220 abandon the practice of D-dimer based thresholds to aid in the decision regarding the initiation of
221 anticoagulation in COVID-19.

222 Studies have noted a clear association between fibrinogen and MA values in other clinical
223 conditions.[14] Marked derangements in fibrinogen has been noted to be common in COVID-19
224 and an analysis of patients with COVID-19 not receiving ECMO and studied at entry into the
225 ICU also demonstrated an association between MA and fibrinogen.[10, 16] In this study,
226 fibrinogen levels were independent predictors of clot strength among patient with other signs of
227 hypercoagulable status.[16] We found fibrinogen to be a much better predictor of magnitude of
228 MA than D-dimer. In our population a fibrinogen of greater than 441 mg/dL had sensitivity of
229 91.2% and specificity 85.7% for detection of MA \geq 68 mm. This finding is of interest given that
230 TEG is not routinely available at many centers and takes specialized training to perform to
231 achieve accurate results. Fibrinogen is a commonly available laboratory tests in most hospital
232 environments and results may be easier to obtain. Thus, it may represent a more practical
233 method for the identification of patients at risk for COVID-19 related hypercoagulability. A new
234 viscoelastic device, the VCM (not yet available in the US but certified in Europe), may offer
235 point-of-care bedside thromboelastograph results which may be useful, especially in austere
236 environments, where fibrinogen testing is not easily available.[17]

237 Other investigators have compared hemostatic changes in COVID-19 to those noted in
238 disseminated intravascular coagulation (DIC) related to sepsis. Unlike DIC; fibrinogen clotting
239 activity in COVID-19 is frequently elevated. Further, coagulation factors such as prothrombin
240 time and activated partial thromboplastin time do not follow the typical pattern usually seen with
241 DIC related consumptive coagulopathy.[18] The physiologic basic of the hypercoagulable state
242 noted in patients with COVID 19 is not well proven. We postulate that an imbalance between
243 procoagulant factors and anticoagulant factors is logical. How elements such as factor VIII,

244 antithrombin, von Willebrand factor, and others explain the observed hypercoagulability has yet
245 to be fully elucidated.

246 Our findings should be interpreted in the context of the study limitations. First, our data is
247 retrospectively derived from a single tertiary care center. The study was limited to severe
248 COVID-19 infection requiring ECMO support to facilitate data collection due to the institutional
249 use of TEG as part of the standard care of these patients. Alterations in platelet function is a
250 known phenomenon in patients on ECMO and the implications of this alteration may affect
251 TEG, inflammatory, and coagulation parameters.[19] Microvesicles are particles derived from
252 platelets or monocytes and carry procoagulant activity. Microvesicles have been associated with
253 VTE and have also been noted in patients on ECMO.[20] The interplay between COVID-19
254 disease and the effects of ECMO may also increase the risk of thromboembolism in these
255 patients. Given these considerations, our selected population may limit generalizability and our
256 findings should be validated in a non-ECMO cohort. Second, all patients in our study were on
257 therapeutic anticoagulation with either heparin or bivalirudin per standard institutional ECMO
258 protocol. Deviation from protocolized dosing of therapeutic anticoagulation was occasionally
259 noted. Several of the patients in this report experienced clotting at cannulation sites despite
260 boluses of heparin and one patient received tissue plasminogen activator in addition to
261 anticoagulation for repetitive pulmonary emboli. There is limited data regarding the use of
262 bivalirudin in patients with COVID-19 on ECMO and further investigation of direct thrombin
263 inhibitors versus traditional heparin anticoagulation is needed. The role of antiplatelet agents
264 should also be explored further in this population. As a result, the effects of anticoagulation and
265 dosing adjustments of these medications on the study outcomes are unknown and may introduce
266 a source of bias. Of note, all findings were consistent when examined for patients on heparin

267 compared to patients on bivalirudin. Finally, although TEG has been validated as a useful marker
268 of hypercoagulability; MA is a surrogate marker for more important clinical outcomes of
269 hypercoagulability such as macro and microthrombosis. Our study lacks suitable sample size to
270 detect the ability of MA, CRP, D-dimer, or fibrinogen to discriminate these clinical outcomes
271 related to hypercoagulability in COVID-19. While fibrinogen and CRP demonstrated a
272 significant increase in patients with macrothrombosis, further prospective study is necessary to
273 better define this relationship.

274 **Conclusion**

275 In critically ill patients with COVID-19, D-dimer appears to have an inverse relationship with
276 degree of hypercoagulability as measured by TEG MA. D-dimer elevation may reflect severity
277 of COVID-19 related sepsis rather than designate patients likely to benefit from anticoagulation.
278 Fibrinogen concentration may represent a more useful marker of hypercoagulability in this
279 population and further study is warranted.

280 **Acknowledgments**

281 We would like to thank all physicians, nurses, respiratory therapists, perfusionists, pharmacists,
282 and ancillary care services who have tirelessly provided care for patients with COVID-19 within
283 the Inova health system.

284







285

286


287 References

- 288 1. Iba, T., et al., *Coagulopathy of Coronavirus Disease 2019*. Crit Care Med, 2020.
- 289 2. Moores, L.K., et al., *Prevention, diagnosis and treatment of venous thromboembolism in*
290 *patients with COVID-19: CHEST Guideline and Expert Panel Report*. Chest, 2020.
- 291 3. Connors, J.M. and J.H. Levy, *COVID-19 and its implications for thrombosis and*
292 *anticoagulation*. Blood, 2020. **135**(23): p. 2033-2040.
- 293 4. Ackermann, M., et al., *Pulmonary Vascular Endothelialitis, Thrombosis, and*
294 *Angiogenesis in Covid-19*. N Engl J Med, 2020.
- 295 5. Magro, C., et al., *Complement associated microvascular injury and thrombosis in the*
296 *pathogenesis of severe COVID-19 infection: A report of five cases*. Transl Res, 2020.
297 **220**: p. 1-13.
- 298 6. Oudkerk, M., et al., *Diagnosis, Prevention, and Treatment of Thromboembolic*
299 *Complications in COVID-19: Report of the National Institute for Public Health of the*
300 *Netherlands*. Radiology, 2020: p. 201629.
- 301 7. Casini, A., et al., *Thromboprophylaxis and laboratory monitoring for in-hospital patients*
302 *with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis*. Swiss
303 Med Wkly, 2020. **150**: p. w20247.
- 304 8. Paranjpe, I., et al., *Association of Treatment Dose Anticoagulation with In-Hospital*
305 *Survival Among Hospitalized Patients with COVID-19*. J Am Coll Cardiol, 2020.
- 306 9. Shah, K., et al., *Magnitude of D-dimer matters for diagnosing pulmonary embolus*. Am J
307 Emerg Med, 2013. **31**(6): p. 942-5.
- 308 10. Tang, N., et al., *Abnormal coagulation parameters are associated with poor prognosis in*
309 *patients with novel coronavirus pneumonia*. J Thromb Haemost, 2020. **18**(4): p. 844-847.
- 310 11. Adam, S.S., N.S. Key, and C.S. Greenberg, *D-dimer antigen: current concepts and future*
311 *prospects*. Blood, 2009. **113**(13): p. 2878-87.
- 312 12. Schutte, T., A. Thijs, and Y.M. Smulders, *Never ignore extremely elevated D-dimer*
313 *levels: they are specific for serious illness*. Neth J Med, 2016. **74**(10): p. 443-448.
- 314 13. Brown, W., et al., *Ability of Thromboelastography to Detect Hypercoagulability: A*
315 *Systematic Review and Meta-Analysis*. J Orthop Trauma, 2020. **34**(6): p. 278-286.
- 316 14. Kupcinskiene, K., et al., *Monitoring of Hypercoagulability by Thromboelastography in*
317 *Bariatric Surgery*. Med Sci Monit, 2017. **23**: p. 1819-1826.
- 318 15. Barnes, G., A. Cuker, and T. Gluckman, *Thrombosis and COVID-19: FAQs For Current*
319 *Practice*. 2020.
- 320 16. Yuriditsky, E., et al., *Thromboelastography Profiles of Critically Ill Patients With*
321 *Coronavirus Disease 2019*. Crit Care Med, 2020.
- 322 17. Brearton, C., et al., *Performance Evaluation of a New Point of Care Viscoelastic*
323 *Coagulation Monitoring System in Major Abdominal, Orthopaedic and Vascular*
324 *Surgery*. Platelets, 2020: p. 1-8.
- 325 18. Panigada, M., et al., *Hypercoagulability of COVID-19 patients in intensive care unit: A*
326 *report of thromboelastography findings and other parameters of hemostasis*. J Thromb
327 Haemost, 2020. **18**(7): p. 1738-1742.
- 328 19. Balle, C.M., et al., *Platelet Function During Extracorporeal Membrane Oxygenation in*
329 *Adult Patients*. Front Cardiovasc Med, 2019. **6**: p. 114.
- 330 20. Meyer, A.D., et al., *Platelet-derived microparticles generated by neonatal extracorporeal*
331 *membrane oxygenation systems*. ASAIO J, 2015. **61**(1): p. 37-42.

332


A**B**

ROC Curve



Area under ROC curve = 0.7066

ROC Curve



Area under ROC curve = 0.9335